Omada Health (NASDAQ:OMDA) Issues Earnings Results

Posted by on Aug 6th, 2026

Omada Health (NASDAQ:OMDA – Get Free Report) released its earnings results on Thursday. The company reported $0.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.10, Zacks reports. Omada Health had a negative net margin of 2.22% and a negative return on equity of 1.82%.

Here are the key takeaways from Omada Health’s conference call:

  • Record Q2 performance: Revenue rose 43% year over year to $88 million, while GAAP gross margin expanded to 73%, net income reached $5 million, and adjusted EBITDA rose to $11 million.
  • Omada ended the quarter with approximately 1.1 million members, up 45% year over year, supported by broad growth across diabetes, hypertension, GLP-1, prevention, and weight-health programs. Members also remained in active treatment nearly 10% longer, while cost of revenue per member declined more than 10%.
  • Commercial momentum remains strong, including new employer wins, expanding PBM channels, a cholesterol launch with a major retailer, and an HCSC expansion covering an additional 1.5 million lives that is expected to begin contributing revenue in the first half of 2027.
  • Management raised full-year 2026 guidance to $334 million-$340 million of revenue and $21 million-$27 million of adjusted EBITDA, citing Q2 strength and visibility into the second half.
  • CEO and co-founder Sean Duffy will become Executive Chair on January 1, 2027, with President Wei-Li Shao succeeding him as CEO; management characterized the transition as planned and emphasized continuity, while noting that second-half revenue growth and EBITDA margins will moderate because of seasonality and ongoing investments.

Omada Health Price Performance

OMDA stock traded up $0.43 during midday trading on Thursday, hitting $19.54. 2,131,836 shares of the company’s stock were exchanged, compared to its average volume of 1,253,720. The firm has a 50 day moving average price of $20.24 and a 200-day moving average price of $16.15. Omada Health has a 12-month low of $10.28 and a 12-month high of $26.92.

Insider Transactions at Omada Health

In other news, CEO Sean P. Duffy sold 12,944 shares of the firm’s stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $20.40, for a total transaction of $264,057.60. Following the completion of the sale, the chief executive officer owned 411,861 shares of the company’s stock, valued at approximately $8,401,964.40. This trade represents a 3.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Steven L. Cook sold 12,337 shares of the company’s stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $23.09, for a total transaction of $284,861.33. Following the completion of the sale, the chief financial officer directly owned 187,209 shares in the company, valued at $4,322,655.81. This represents a 6.18% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 206,406 shares of company stock valued at $4,191,483. 6.38% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. PDT Partners LLC bought a new position in Omada Health in the fourth quarter worth about $166,000. Barclays PLC lifted its holdings in shares of Omada Health by 14.6% in the 4th quarter. Barclays PLC now owns 14,850 shares of the company’s stock worth $234,000 after purchasing an additional 1,888 shares during the last quarter. Wilmington Savings Fund Society FSB acquired a new position in Omada Health during the 3rd quarter valued at approximately $287,000. BNP Paribas Financial Markets bought a new stake in Omada Health in the third quarter valued at $278,000. Finally, WINTON GROUP Ltd acquired a new position in shares of Omada Health during the third quarter valued at $217,000.

Key Stories Impacting Omada Health

Here are the key news stories impacting Omada Health this week:

  • Positive Sentiment: Q2 earnings beat expectations. Omada reported adjusted earnings of $0.15 per share, compared with the Zacks consensus estimate of $0.05 and a loss of $0.09 a year earlier. A separate report cited EPS of $0.08 versus expectations for a $0.02 loss, reflecting differences in reporting methodology. Omada Health Q2 earnings and revenues top estimates
  • Positive Sentiment: Growth remained strong. Second-quarter revenue rose 43% year over year, while total members increased 45%. Gross margin reached a new quarterly record, supporting the investment case for Omada’s virtual chronic-care platform. Omada Health reports second-quarter 2026 results
  • Positive Sentiment: Revenue guidance exceeded Wall Street expectations. Management forecast fiscal 2026 revenue of $334 million to $340 million, above the $327.2 million consensus estimate. This suggests continued demand and gives investors greater confidence in the company’s growth trajectory.
  • Neutral Sentiment: CEO transition announced. Co-founder Sean Duffy will become executive chair on January 1, 2027, while President Wei-Li Shao becomes CEO. The planned succession provides continuity, though investors may monitor execution and strategy under the incoming leadership. Omada Health announces CEO transition
  • Negative Sentiment: CEO insider selling creates a modest overhang. Sean Duffy sold 12,944 shares for approximately $264,000, reducing his direct holdings by 3.05%. The sale is relatively small compared with his remaining stake, but insider selling can weigh on sentiment, particularly alongside a leadership change.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $28.00 price target on shares of Omada Health in a report on Friday, May 8th. Canaccord Genuity Group increased their target price on Omada Health from $24.00 to $28.00 and gave the stock a “buy” rating in a research report on Tuesday, July 21st. Citizens Jmp lifted their target price on Omada Health from $21.00 to $27.00 and gave the company a “market outperform” rating in a report on Monday, July 20th. Evercore reissued an “outperform” rating and set a $20.00 price target on shares of Omada Health in a research report on Friday, May 8th. Finally, Weiss Ratings lowered Omada Health from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, July 13th. Eleven equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Omada Health currently has an average rating of “Moderate Buy” and an average target price of $24.75.

View Our Latest Research Report on Omada Health

Omada Health Company Profile

(Get Free Report)

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.

Featured Stories

Receive News & Ratings for Omada Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omada Health and related companies with MarketBeat.com's FREE daily email newsletter.